Substance / Medication

Ofloxacin

Overview

Active Ingredient
ofloxacin
RxNorm CUI
7623

Indications

Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: * Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS : Gram - positive bacteria : Gram - negative bacteria : Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS :

Labeler: A-S Medication SolutionsUpdated: 2026-01-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ofloxacin Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see Warnings).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

7 trials linked to this intervention

7
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis.
Setia Maninder S, Shinde Santosh S, Jerajani Hemangi R et al. · Trop Med Int Health · 2011
PMID: 21914093Meta-Analysis
Aqueous Humour Ofloxacin Concentration after Topical Instillation in Patients with Dry Eye Disease.
Kagkelaris Konstantinos, El Mubarak Mohamed A, Plotas Panagiotis et al. · Medicina (Kaunas) · 2022
PMID: 36013498RCTFull text (PMC)
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Chigutsa Emmanuel, Meredith Sandra, Wiesner Lubbe et al. · Antimicrob Agents Chemother · 2012
PMID: 22564839RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ofloxacin (substance)
SNOMED CT
387551000
UMLS CUI
C0028902
RxNorm CUI
7623
Labeler
A-S Medication Solutions

Clinical Data

This intervention maps to 25 entities in the Ltrl knowledge graph.

20
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.